Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 68, Issue -, Pages 37-53Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2022.10.001
Keywords
Respiratory syncytial virus; MRNA vaccine; Fusion protein; Prospect
Categories
Funding
- National Natural Science Foundation of China [82004204]
- Qinglan Project of Jiangsu Province of China, Colleges and universities in Jiangsu Province Natural Science Research [22KJA360004]
- Natural Science Foundation of Nanjing University of Chinese Medicine [NZY82004204]
- CACM [2021-QNRC2-B14]
Ask authors/readers for more resources
Respiratory syncytial virus (RSV) is a major pathogen causing bronchitis and pneumonia in infants and the elderly. No approved preventative vaccine for RSV infection currently exists. However, advances in understanding the RSV surface fusion glycoprotein have provided a new target for vaccine development. Among the six different approaches to preventative RSV therapeutics, mRNA vaccines have shown the most promising results.
Respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus that is the primary etiologic pathogen of bronchitis and pneumonia in infants and the elderly. Currently, no preventative vaccine has been approved for RSV infection. However, advances in the characterization, and structural resolution, of the RSV surface fusion glycoprotein have revolutionized RSV vaccine development by providing a new target for pre-ventive interventions. In general, six different approaches have been adopted in the development of preventative RSV therapeutics, namely, particle-based vaccines, vector-based vaccines, live-attenuated or chimeric vaccines, subunit vaccines, mRNA vaccines, and monoclonal antibodies. Among these preventive interventions, MVA-BN-RSV, RSVpreF3, RSVpreF, Ad26. RSV.preF, nirsevimab, clesrovimab and mRNA-1345 is being tested in phase 3 clinical trials, and displays the most promising in infant or elderly populations. Accompanied by the huge success of mRNA vaccines in COVID-19, mRNA vaccines have been rapidly developed, with many having entered clinical studies, in which they have demonstrated encouraging results and acceptable safety profiles. In fact, Moderna has received FDA approval, granting fast-track designation for an investigational single-dose mRNA-1345 vaccine against RSV in adults over 60 years of age. Hence, mRNA vaccines may represent a new, more successful, chapter in the continued battle to develop effective preventative measures against RSV. This review discusses the structure, life cycle, and brief history of RSV, while also presenting the current advancements in RSV pre-ventatives, with a focus on the latest progress in RSV mRNA vaccine development. Finally, future prospects for this field are presented.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available